<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701857</url>
  </required_header>
  <id_info>
    <org_study_id>07-0612-04</org_study_id>
    <secondary_id>P30CA023074</secondary_id>
    <secondary_id>UARIZ-07-0612-04</secondary_id>
    <secondary_id>UARIZ-BIO07067</secondary_id>
    <secondary_id>UARIZ-SRC18084</secondary_id>
    <secondary_id>LILLY-UARIZ-07-0612-04</secondary_id>
    <nct_id>NCT00701857</nct_id>
  </id_info>
  <brief_title>Pemetrexed, Cisplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer</brief_title>
  <official_title>Phase I Study of Concomitant Pemetrexed and CDDP Plus Radiation Therapy in Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal (GEJ) Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways&#xD;
      to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Cisplatin may make&#xD;
      tumor cells more sensitive to radiation therapy. Giving pemetrexed together with cisplatin&#xD;
      and radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of pemetrexed when&#xD;
      given together with cisplatin and radiation therapy in treating patients with stage III or&#xD;
      stage IV esophageal cancer or gastroesophageal junction cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To establish the maximum tolerated dose of pemetrexed disodium in combination with&#xD;
           cisplatin and standard-dose radiotherapy in patients with stage III or IV esophageal or&#xD;
           gastroesophageal junction carcinoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To specifically characterize the toxicity profile of this regimen.&#xD;
&#xD;
        -  To investigate, preliminarily, the anti-tumor activity of this regimen, as measured by&#xD;
           standard response criteria (RECIST criteria), in patients with measurable disease.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of pemetrexed disodium.&#xD;
&#xD;
      Patients receive pemetrexed disodium IV over 10 minutes on days 1, 15, and 29 and cisplatin&#xD;
      IV over 10 minutes on days 1, 8, 15, 22, and 29. Patients also undergo external beam&#xD;
      radiotherapy once daily, 5 days a week, for up to 6 weeks.&#xD;
&#xD;
      After completion of study therapy, patients are followed for 30 days and then every 3 months&#xD;
      for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD) of pemetrexed</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response (complete response, partial response, progressive disease, and stable disease) as measured by RECIST criteria</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Pemetrexed, Cisplatin, Radiation Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concomitant Pemetrexed and CDDP Plus Radiation Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Standard weekly dose</description>
    <arm_group_label>Pemetrexed, Cisplatin, Radiation Therapy</arm_group_label>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Biweekly pemetrexed dose escalation</description>
    <arm_group_label>Pemetrexed, Cisplatin, Radiation Therapy</arm_group_label>
    <other_name>Pemetrexed disodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Weekly standard dose radiation therapy</description>
    <arm_group_label>Pemetrexed, Cisplatin, Radiation Therapy</arm_group_label>
    <other_name>RT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of esophageal or gastroesophageal junction carcinoma&#xD;
&#xD;
               -  Stage III or IV disease&#xD;
&#xD;
          -  Treatment with chemoradiotherapy is considered appropriate&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Clinically significant pleural or pericardial effusions or ascites allowed provided&#xD;
             they were drained prior to study entry&#xD;
&#xD;
               -  No pleurodesis within the past 2 weeks&#xD;
&#xD;
          -  Controlled brain metastasis allowed provided patient is clinically stable with no&#xD;
             signs of progression by MRI or CT scan of the brain ≥ 60 days after completion of&#xD;
             treatment AND is asymptomatic and does not require steroids&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  WBC ≥ 2,500/mm^3&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Total bilirubin normal&#xD;
&#xD;
          -  Alkaline phosphatase AND AST and ALT meeting the following criteria:&#xD;
&#xD;
               -  Alkaline phosphatase normal AND AST or ALT ≤ 3 times upper limit of normal (ULN)&#xD;
                  (≤ 5 times ULN for patients with liver metastases)&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 5 times ULN AND AST or ALT normal&#xD;
&#xD;
          -  Creatinine clearance ≥ 45 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study therapy&#xD;
&#xD;
          -  Able to take folic acid, vitamin B_12, or corticosteroids&#xD;
&#xD;
          -  No known severe hypersensitivity reaction to study drugs&#xD;
&#xD;
          -  No uncontrolled serious active infection&#xD;
&#xD;
          -  No pre-existing peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  No significant cardiac disease, including any of the following:&#xD;
&#xD;
               -  Uncontrolled high blood pressure&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Congestive heart failure within the past 6 months&#xD;
&#xD;
               -  Left ventricular ejection fraction below the lower limit of normal&#xD;
&#xD;
               -  Myocardial infarction within the past year&#xD;
&#xD;
               -  Serious cardiac arrhythmias requiring medication&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior systemic therapy regimens&#xD;
&#xD;
          -  No prior radiotherapy to gastric/esophageal fields&#xD;
&#xD;
          -  No aspirin or other NSAID before and after pemetrexed disodium administration&#xD;
&#xD;
          -  No concurrent colony-stimulating factors (CSF) to maintain WBC and ANC eligibility&#xD;
             values&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emad Elquza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>June 18, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

